Skip to main content
SpringerLink
Log in

Analysis of mdm2 and p53 Gene Alterations in Glioblastomas and its Correlation with Clinical Factors

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Malignant gliomas are the most frequent primary brain tumors. Recent studies defined several genetic markers, which might characterize molecular-biological subsets of glioblastomas with probably prognostic implications. To elucidate the involvement of murine-double-minute (mdm)2 gene amplifications and mutations of the tumor suppressor gene p53 in the tumorigenesis of malignant gliomas we analyzed a series of 75 glioblastomas. The p53 mutations occur in one-third of glioblastomas, mdm2 amplifications were found in 13% of cases. Our analysis revealed a hot spot in the p53 gene locus in codon 156, the same point mutation was detected in 4 tumor samples. None of the mdm2 amplified tumors had p53 mutations, supporting the hypothesis, that mdm2 amplifications are alternative mechanisms for p53 inactivation. Patients with p53 mutated tumors were significantly younger characterized by a mean age of 44 years. Additionally association with longer overall survival could be detected for this subgroup of patients. In our study, survival estimation revealed a significant correlation of mdm2 gene amplification with shorter survival time, and support the hypothesis, that mdm2 oncogene activation appears to occur late in tumor progression and may be characteristic as negative prognostic marker.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bamberg M, Hess CF: Radiation therapy of malignant gliomas. Onkologie 15: 178–189, 1992

    Google Scholar 

  2. Schiebe M, Ohneseit P, Rodemann HP, Bamberg M: Frequency of tumor suppressor gene mutations in glioblastoma multiforme and its clinical value. p53-Meeting Hamburg, May Vol 1, 39, 1995

    Google Scholar 

  3. Shin TH, Peterson AJ, Kudlow JE: p53 stimulates transcription from the human transforming growth factor alpha promotor: a potential growth-stimulatory role for p53. Mol Cell Biol 15: 4694–4701, 1995

    Google Scholar 

  4. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H: Loss of heterozygosity on chromosome 10 is more extensive in primary than in secondary glioblastomas. Lab Invest 80: 65–72, 2000

    Google Scholar 

  5. Von Deimling A, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 13: 328–338, 1995

    Google Scholar 

  6. Biernat W, Debiec-Rychter M, Liberski PP: Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas. Pol J Pathol 49: 267–271, 1998

    Google Scholar 

  7. Yahanda AN, Brunner JM, Donehower LA, Morrison RS: Astrocytes derived from p53-deficient mice provides a multistep in vitro model for development of malignant gliomas. Mol Cell Biol 15: 4249–4259, 1995

    Google Scholar 

  8. Shapiro WR, Shapiro JR: Biology and treatment of malignant glioma. Oncology(Huntington) 12(2): 233–240, 1998

    Google Scholar 

  9. Hulsebos TI, Oskam NT, Troost D, Leensta S, Biljeveld EH: Dynamics of genetic alterations associated with glioma recurrence. Genes Chromosomes Canc 23: 153–158, 1998

    Google Scholar 

  10. Reifenberger G, Reifenberger J, Ichimura K, Collins VP: Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site. Canc Res 55: 731–734, 1995

    Google Scholar 

  11. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and over expression of mdm2 in primary glioblastomas. J Neuropathol Exp Neurol 56: 180–185, 1997

    Google Scholar 

  12. Ehrmann J, Kolar Z, Vojtesek B, Kala M, Komenda S, Oulton A: Prognostic factors in astrocytomas: relationship of p53, MDM2, BCL 2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma 44: 299–304, 1997

    Google Scholar 

  13. Rainov G, Dobberstein K, Bahn H, Holzhausen H, Lautenschläger C, Heidecke V, Burkert W: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor-gene products on survival. J Neuro-Oncol 35: 13–28, 1997

    Google Scholar 

  14. Korkolopoulou P, Christodoulou P, Kouzelis K et al.: mdm2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Canc 75(9): 1269–1278, 1997

    Google Scholar 

  15. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or BCL-2 genes. Brain Pathol 8: 655–667, 1998

    Google Scholar 

  16. Kleihues P, Burger P, Scheithauer BW: The new WHO classification of brain tumors. Brain Pathol 3: 255–268, 1993

    Google Scholar 

  17. Lahiri DK, Nurnberger JI: A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucl Acid Res 19: 5444, 1991

    Google Scholar 

  18. Hunter S, Abbott K, Vijay A, Varma MD, Olson JJ, Barnett DW, James D: Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification. J Neuropathol Exp Neurol 54: 57–64, 1995

    Google Scholar 

  19. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U, Reifenberger G: Amplification and over expression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Canc Res 59: 6091–6096, 1999

    Google Scholar 

  20. Perry A, Jenkins RB, O'Fallon JR, Schaefer PL, Kimmel DW, MahoneyM, Scheithauer BW, Smith SM, Hill EM, Sebo TJ, Levitt R, Krook J, Tschetter LK, Morton RF, Buckner JC: Clinico pathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. Cancer 86(4): 672–683, 1999

    Google Scholar 

  21. Rieske P, Kordek R, Bartkowiak J, Debiec-Rychter M, Bienhat W, Liberski PP: A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas. Pol J Pathol 49: 145–149, 1998

    Google Scholar 

  22. Chen J, Lin J, Levine AJ: Regulation of transcription functions of the p53 tumor suppressor by the mdm2 oncogene. Mol Med 1: 142–152, 1995

    Google Scholar 

  23. Chen J, Wu X, Lin J, Levine AJ: MDM2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445–2452, 1996

    Google Scholar 

  24. Olson JJ, Barnett D, Yang J, Assietti R, Cotsonis G, James CD: Gene amplification as a prognostic factor in primary brain tumors. Clin Canc Res 4: 215–222, 1998

    Google Scholar 

  25. Zulch KJ: Brain Tumors: Their Biology and Pathology. 3rd edn, Springer, New York 1986

    Google Scholar 

  26. Schiebe M, Ohneseit P, Meyermann R, Rodemann HP, Bamberg M: Prognostische Wertigkeit genetischer Marker (MDM2, 9p, 10q, 11p15, p53) in malignen Gliomen. Strahlenther Onkol 174: 15, 1998

    Google Scholar 

  27. Kleihues P, Ohgaki H: Phenotype vs genotype in the evolution of astrocytic brain tumors. Toxicol Pathol 28: 164–170, 2000

    Google Scholar 

  28. Nieder C, Petersen S, Petersen C, Thames HD: The challenge of p53 as prognostic and predictive factor in gliomas. Canc Treat Rev 26: 67–73, 2000

    Google Scholar 

  29. Galanis E, Bucker J, Kimmel D, Jenins R, Alderete B, O'Fallon J, Wang CH, Scheithauer BW, James CD: Gene amplification as a prognostic factor in primary and secondary high grade malignant gliomas. Int J Oncol 13(4): 717–724, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiotherapy, Department of Radiooncology and Radiotherapy, Academic Teaching Hospital, Braunschweig, Germany

    Martina Schiebe & Wolfgang Hoffmann

  2. Section of Radiobiology and Environmental Research, Academic Teaching Hospital, Braunschweig, Germany

    Petra Ohneseit & Hans-Peter Rodemann

  3. Department of Neuropathology, University of Tübingen, Germany

    R. Meyermann

  4. Academic Teaching Hospital, Braunschweig, Germany

    R. Meyermann

  5. Department of Radiotherapy, Academic Teaching Hospital, Braunschweig, Germany

    Michael Bamberg

Authors
  1. Martina Schiebe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Petra Ohneseit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolfgang Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Meyermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hans-Peter Rodemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Bamberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiebe, M., Ohneseit, P., Hoffmann, W. et al. Analysis of mdm2 and p53 Gene Alterations in Glioblastomas and its Correlation with Clinical Factors. J Neurooncol 49, 197–203 (2000). https://doi.org/10.1023/A:1006410702284

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006410702284

Search

Navigation